Additionally, the incidence of grade ≥3 leukopenia and/or grade ≥3 neutropenia was lower in patients who received prophylaxis with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) (23.3%; 10/43) in comparison to those without prophylaxis (36.1%; 13/36) (Supplementary Table 2). The gene discussed is CSF3; the disease is Decreased total neutrophil count.